Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
8M2D in Healthy Participants and Early AD Participants
NCT07568041Phase 1Not yet recruiting
- Sponsor
- Cenna Biosciences Inc.
- Start
- Sep 2026
- Primary completion
- Sep 2027
- Modality
- Peptides
01
Overview
Phase 1, randomised, double-blind trial of 8M2D in Alzheimer's disease (AD) (4 arms), sponsored by Cenna Biosciences Inc. Primary endpoints: Treatment-Emergent Adverse Events at Day 44, Treatment-Emergent Adverse Events Leading to Discontinuation at Day 14 and 12 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
8M2D
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT07568041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07568041.